title: Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinson's disease.
abstract: OBJECTIVE
  Some studies have suggested a potential risk of heart failure in patients with Parkinson's disease receiving dopamine (DA) agonists. However, the results are conflicting. We used VigiBase®, the World Health Organization (WHO) Global Individual Case Safety Reports (ICSRs) database, to investigate a potential signal strengthening of heart failure with DA agonists in Parkinsonian patients older than 45 years.
  
  
  METHODS
  A case/non-case (disproportionality) analysis was performed in Vigibase® using ICSRs registered between 1978 and May 2016. The signal of disproportionality was calculated using reporting odds ratios (ROR). In our study, 154 ICSRs of heart failure occurring in 154 Parkinsonian patients (mean age 69.6 years, 51 % women) treated with DA agonists were included.
  
  
  CONCLUSIONS
  There was a significant signal between occurrence of heart failure and exposure to pergolide or cabergoline in particular and ergot derivatives in general. In contrast, none signal was found for rotigotine, pramipexole, apomorphine, or ropinirole in particular and non-ergot derivatives in general. The present study underlines the importance to prescribe as DA agonists in Parkinsonian patients only non-ergot derivatives, excluding ergot drugs.
authors: Laboratoire de Pharmacologie Médicale et Clinique de la Faculté de Médecine et du Centre Hospitalier Universitaire de Toulouse, Toulouse, France.|Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.|INSERM UMR 1027, Faculté de Médecine, Université de Toulouse, Toulouse, France.|CIC INSERM 1436, Université et Centre Hospitalier Universitaire de Toulouse, Toulouse, France.|NeuroToul Centre of Excellence in Neurodegeneration, Université et Centre Hospitalier Universitaire deToulouse, Toulouse, France.
authors: François
authors: F
authors: Montastruc
authors: Laboratoire de Pharmacologie Médicale et Clinique de la Faculté de Médecine et du Centre Hospitalier Universitaire de Toulouse, Toulouse, France.|Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
authors: Florence
authors: F
authors: Moulis
authors: Laboratoire de Pharmacologie Médicale et Clinique de la Faculté de Médecine et du Centre Hospitalier Universitaire de Toulouse, Toulouse, France.|Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
authors: Mélanie
authors: M
authors: Araujo
authors: Laboratoire de Pharmacologie Médicale et Clinique de la Faculté de Médecine et du Centre Hospitalier Universitaire de Toulouse, Toulouse, France.|Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
authors: Leila
authors: L
authors: Chebane
authors: Laboratoire de Pharmacologie Médicale et Clinique de la Faculté de Médecine et du Centre Hospitalier Universitaire de Toulouse, Toulouse, France.|CIC INSERM 1436, Université et Centre Hospitalier Universitaire de Toulouse, Toulouse, France.|NeuroToul Centre of Excellence in Neurodegeneration, Université et Centre Hospitalier Universitaire deToulouse, Toulouse, France.|INSERM UMR 825, Université de Toulouse, Toulouse, France.
authors: Olivier
authors: O
authors: Rascol
authors: Laboratoire de Pharmacologie Médicale et Clinique de la Faculté de Médecine et du Centre Hospitalier Universitaire de Toulouse, Toulouse, France. jean-louis.montastruc@univ-tlse3.fr.|Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. jean-louis.montastruc@univ-tlse3.fr.|INSERM UMR 1027, Faculté de Médecine, Université de Toulouse, Toulouse, France. jean-louis.montastruc@univ-tlse3.fr.|CIC INSERM 1436, Université et Centre Hospitalier Universitaire de Toulouse, Toulouse, France. jean-louis.montastruc@univ-tlse3.fr.|NeuroToul Centre of Excellence in Neurodegeneration, Université et Centre Hospitalier Universitaire deToulouse, Toulouse, France. jean-louis.montastruc@univ-tlse3.fr.
authors: Jean-Louis
authors: JL
authors: Montastruc
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D016208:Databases, Factual; D018491:Dopamine Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D004876:Ergot Alkaloids / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006333:Heart Failure / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*
chemical_list: D018491:Dopamine Agonists; D004876:Ergot Alkaloids
keywords: Dopamine agonists; Ergot derivatives; Heart failure; Parkinson’s disease; Pramipexole; Ropinirole